Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leon Aarons

Showing results (41-50 of 123) with videos related to

Pageof 13
Sort By:
British Journal of Clinical Pharmacology|October 19, 2020
Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patientsAurélie Lombard, Hitesh Mistry, Leon Aarons, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2016
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size dataThierry Wendling, Hitesh Mistry, Kayode Ogungbenro, et al.
European Journal of Clinical Pharmacology|March 9, 2007
Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEMGrant Langdon, Ivelina Gueorguieva, Leon Aarons, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 9, 2009
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDesMarylore Chenel, François Bouzom, Leon Aarons, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 19, 2015
Designing More Efficient Preclinical Experiments: A Simulation Study in Chemotherapy-Induced MyelosupressionEmma C Martin, Leon Aarons, James W T Yates
Therapeutic Drug Monitoring|January 28, 2003
A Bayesian method based on clotting factor activity for the prediction of maintenance warfarin dosage regimensMaria Pitsiu, Eva M Parker, Leon Aarons, et al.
Cancer Chemotherapy and Pharmacology|May 26, 2016
Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animalsEmma C Martin, Leon Aarons, James W T Yates
Journal of Pharmacokinetics and Pharmacodynamics|December 16, 2018
Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugsNicola Melillo, Leon Aarons, Paolo Magni, et al.
Cancer Chemotherapy and Pharmacology|July 29, 2018
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse modelsEmma C Martin, Leon Aarons, James W T Yates
Pharmaceutical Research|September 24, 2005
Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptanIvelina Gueorguieva, Ivan A Nestorov, Leon Aarons, et al.
Pageof 13

Showing results (41-50 of 123) with videos related to

Sort By:
Pageof 13
British Journal of Clinical Pharmacology|October 19, 2020
Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patientsAurélie Lombard, Hitesh Mistry, Leon Aarons, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2016
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size dataThierry Wendling, Hitesh Mistry, Kayode Ogungbenro, et al.
European Journal of Clinical Pharmacology|March 9, 2007
Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEMGrant Langdon, Ivelina Gueorguieva, Leon Aarons, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 9, 2009
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDesMarylore Chenel, François Bouzom, Leon Aarons, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 19, 2015
Designing More Efficient Preclinical Experiments: A Simulation Study in Chemotherapy-Induced MyelosupressionEmma C Martin, Leon Aarons, James W T Yates
Therapeutic Drug Monitoring|January 28, 2003
A Bayesian method based on clotting factor activity for the prediction of maintenance warfarin dosage regimensMaria Pitsiu, Eva M Parker, Leon Aarons, et al.
Cancer Chemotherapy and Pharmacology|May 26, 2016
Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animalsEmma C Martin, Leon Aarons, James W T Yates
Journal of Pharmacokinetics and Pharmacodynamics|December 16, 2018
Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugsNicola Melillo, Leon Aarons, Paolo Magni, et al.
Cancer Chemotherapy and Pharmacology|July 29, 2018
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse modelsEmma C Martin, Leon Aarons, James W T Yates
Pharmaceutical Research|September 24, 2005
Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptanIvelina Gueorguieva, Ivan A Nestorov, Leon Aarons, et al.
Pageof 13